SNS01-T: Phase Ib/IIa amended

Senesco said it amended an open-label, dose-escalation, U.S. Phase Ib/IIa trial of twice-weekly IV SNS01-T for 6 weeks in patients with relapsed or refractory MM to include patients with DLBCL and MCL...